TABLE 3.
Comparison of Baseline Information Between 2 JAK1/2 Status
| n (%) | |||
|---|---|---|---|
| JAK1/2 Wild | JAK1/2 Mutated | P | |
| Age (y) | 0.42 | ||
| ≤40 | 14 (51.9) | 6 (75.0) | |
| >40 | 13 (48.1) | 2 (25.0) | |
| Sex | 1.00 | ||
| Male | 21 (77.8) | 7 (87.5) | |
| Female | 6 (22.2) | 1 (12.5) | |
| Adenocarcinoma | 0.70 | ||
| Yes | 10 (37.0) | 4 (50.0) | |
| No | 17 (63.0) | 4 (50.0) | |
| Lynch syndrome | 1.00 | ||
| Lynch | 19 (70.4) | 6 (75.0) | |
| Sporadic | 8 (29.6) | 2 (25.0) | |
| TMB>20 | 0.009 | ||
| No | 0 (0.0) | 3 (37.5) | |
| Yes | 27 (100.0) | 5 (62.5) | |
| Tumor location | 1.000 | ||
| Left-sided | 16 (59.3) | 5 (62.5) | |
| Right-sided | 11 (40.7) | 3 (37.5) | |
| RAS mutation | 0.42 | ||
| Wild-type | 13 (48.1) | 2 (25.0) | |
| Mutant-type | 14 (51.9) | 6 (75.0) | |
| PIK3CA mutation | 0.44 | ||
| Wild-type | 12 (44.4) | 5 (62.5) | |
| Mutant-type | 15 (55.6) | 3 (37.5) | |
| Clinical response | 0.032 | ||
| CR_PR | 15 (55.6) | 8 (100.0) | |
| SD_PD | 12 (44.4) | 0 (0.0) | |
Bold values are statistically significant at P<0.05.
CR indicates complete response; JAK1/2, Janus kinases 1 and 2; PD, progressive disease; PR, partial response; SD, stable disease; TMB, tumor mutational burden.